IL-6 has been shown to recruit MDSCs and M2 macrophages to the TME, which indicates that targeting IL-6 would reduce immune suppression through decreasing PD-L1 levels as well as preventing tumour-induced assistance from the immune system through MDSCs and M2 macrophages [36]. The gene discussed is IL6; the disease is neoplasm.